H. Lundbeck specializes in the development, production and marketing of medicines for the treatment of psychiatric and neurological disorders. Net sales break down by family of products as follows:
- antidepressants and anti-anxiolitics (53%): marketed under the Cipralex and Lexapro brands;
- treatments for Alzheimer's disease (17,2%): Ebixa brand;
- other (29,8%): medicines for Parkinson's disease, sleep disorders, etc.
The group also had, at the end of 2011, a portfolio of 8 psychiatric products in development phase (including 6 in phase III and 2 in phase II).
Net sales break down geographically as follows: Europe (51.2%), the United States (26.6%) and other (22.2%).